Does Niacin Lipid Profile Randomized Trial work?

The current Migaku evidence database contains 2 reusable source documents for Niacin Lipid Profile Randomized Trial. This answer focuses on strength of evidence and what the studies can or cannot prove. - Elevated low-density lipoprotein cholesterol (LDL-C) is a key modifiable risk factor in atherosclerotic cardiovascular diseases. [Liu HH (2026); evidence level 3] - While statins are the first-line therapy for LDL-C management, challenges such as limited additional benefits with dose escalation and an increased risk of adverse drug reactions at higher doses remain. [Liu HH (2026); evidence level 3] - Ezetimibe monotherapy reduces LDL-C levels by approximately 17.1-25.9% and significantly lowers the risk of major adverse cardiovascular events compared with placebo. [Liu HH (2026); evidence level 3] - Since its discovery over half a century ago, Lp(a) has attracted considerable interest due to its strong, genetically determined association with atherosclerotic cardiovascular disease (ASCVD), independent of traditional lipid risk factors. [Domański Igor (2026); evidence level 4] - Elevated Lp(a) concentrations—particularly those above 50 mg/dL—have been strongly linked to an increased risk of myocardial infarction, ischemic stroke, peripheral artery disease, heart failure, and aortic valve stenosis. [Domański Igor (2026); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.